Deepc, a Munich-based AI-driven software company for radiologists, has announced that it has acquired medical imaging software, the Osimis Platform.
Deepc’s bespoke operating system for radiology, DeepcOS, is designed to provide clinicians with access to a wide variety of AI-powered radiology solutions, with the acquisition of Belgian developer Liege adding enhanced imaging to the suite.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Deepc said that the integration of the Osimis imaging system into DeepcOS will allow for much more streamlined workflows and allow users of both systems to seamlessly transfer information between different applications.
Terms of the deal were not disclosed.
Deepc CEO Franz Pfister said: “At Deepc, we are dedicated to supporting clinicians and their institutions with a unified, scalable platform that delivers value and efficiency across the radiology workflow. Our acquisition of the Osimis platform underscores our commitment to delivering cutting-edge solutions and unparalleled service to our customers.”
The acquisition has the added benefit for Deepc of further consolidating its place in the rapidly growing AI imaging market which itself has seen a significant number of mergers and acquisitions over the past year as firms rush to establish footholds in the AI market.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLast month, the US-based Veracyte acquired minimal residual disease test developer C2i genomics in a deal worth up to $95m. In December 2023, 4D Medical signed an agreement to acquire Imbio, a US-based provider of lung and heart AI-driven technology.
It also comes at a strong time for the imaging market after the GlobalData Pipeline Products Database revealed that this year, imaging agents account for nearly 60% of all diagnostic imaging devices in development, with 50% of pipeline imaging agents intended for use in oncology.
Osimis CEO Peter Morel said: “We see tremendous potential in joining forces with Deepc, Together, we will be able to accelerate innovation, expand our reach, and deliver even greater value to all of our Deepc and Osimis customers. We are excited about the opportunities that lie ahead.”
It comes as the US Food and Drug Administration focuses on how AI can be used to support clinical trials as part of day three of the SCOPE Summit in Orlando.
